Cite
HARVARD Citation
Morton, G. et al. (n.d.). Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Early toxicity and quality-of life results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy. Radiotherapy and oncology. 122 (1), pp. 87-92. [Online].